Xiao-Yan Yi1, Shi-Fen Ni2, Mohammad Rasoul Ghadami3, Hua-Qing Meng2, Ming-Yan Chen4, Li Kuang2, Yu-Qing Zhang5, Li Zhang1, Xin-Yu Zhou6. 1. The First Branch, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 3. Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. 4. Department of Statistics, University of Toronto, 100 St. George Street, Toronto, Canada. 5. Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 6. Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: xinyu973@126.com.
Abstract
OBJECTIVE: To assess the efficacy and tolerability of trazodone compared with placebo in patients with insomnia. METHODS: Electronic databases were searched and relevant reports were hand-screened to identify eligible trials. Only randomized placebo-controlled trials were included. Standardized mean differences (SMD) and the odds ratios (OR) were estimated using a random-effect model. Primary efficacy outcomes included sleep efficiency (SE%) and self-reported sleep quality (SQ). Secondary efficacy outcomes included sleep latency (SL), total sleep time (TST), the number of awakenings (NAs), waking time after sleep onset (WASO). Tolerability outcome was measured by the number of patients who discontinued for adverse events and acceptability outcome was measured by the number of patients who discontinued for all causes. RESULTS: Seven trials involving 429 patients were included. There was no significant improvement for trazodone in SE% (SMD = 0.09, 95% confidence interval (CI) -0.19 to 0.38, P = 0.53) with a non-significant heterogeneity (I2 = 0%, P = 0.59). However, patients receiving trazodone perceived better SQ than those receiving the placebo (SMD = -0.41, 95% CI -0.82 to -0.00, P = 0.05) with a non-significantly moderate heterogeneity (I2 = 65%, P = 0.06). As to secondary efficacy outcomes, we only found a significant reduction for trazodone in NAs (SMD = -0.51, 95%CI -0.97 to -0.05) compared to the placebo, with non-significant differences found in SL, TST, or WASO between trazodone and placebo. Moreover, no significant difference was found in the outcome of tolerability or acceptability. CONCLUSIONS: Trazodone was effective in sleep maintenance by decreasing the number of early awakenings and it could significantly improve perceived sleep quality, although there were no significant improvements in sleep efficiency or other objective measures. Trazodone however, presented good tolerance in the short-term treatment of insomnia.
OBJECTIVE: To assess the efficacy and tolerability of trazodone compared with placebo in patients with insomnia. METHODS: Electronic databases were searched and relevant reports were hand-screened to identify eligible trials. Only randomized placebo-controlled trials were included. Standardized mean differences (SMD) and the odds ratios (OR) were estimated using a random-effect model. Primary efficacy outcomes included sleep efficiency (SE%) and self-reported sleep quality (SQ). Secondary efficacy outcomes included sleep latency (SL), total sleep time (TST), the number of awakenings (NAs), waking time after sleep onset (WASO). Tolerability outcome was measured by the number of patients who discontinued for adverse events and acceptability outcome was measured by the number of patients who discontinued for all causes. RESULTS: Seven trials involving 429 patients were included. There was no significant improvement for trazodone in SE% (SMD = 0.09, 95% confidence interval (CI) -0.19 to 0.38, P = 0.53) with a non-significant heterogeneity (I2 = 0%, P = 0.59). However, patients receiving trazodone perceived better SQ than those receiving the placebo (SMD = -0.41, 95% CI -0.82 to -0.00, P = 0.05) with a non-significantly moderate heterogeneity (I2 = 65%, P = 0.06). As to secondary efficacy outcomes, we only found a significant reduction for trazodone in NAs (SMD = -0.51, 95%CI -0.97 to -0.05) compared to the placebo, with non-significant differences found in SL, TST, or WASO between trazodone and placebo. Moreover, no significant difference was found in the outcome of tolerability or acceptability. CONCLUSIONS:Trazodone was effective in sleep maintenance by decreasing the number of early awakenings and it could significantly improve perceived sleep quality, although there were no significant improvements in sleep efficiency or other objective measures. Trazodone however, presented good tolerance in the short-term treatment of insomnia.
Authors: Kevin M Swift; Connie L Thomas; Thomas J Balkin; Emily G Lowery-Gionta; Liana M Matson Journal: J Clin Sleep Med Date: 2022-09-01 Impact factor: 4.324
Authors: Marianna Mazza; Emanuele Caroppo; Giuseppe Marano; Georgios D Kotzalidis; Carla Avallone; Giovanni Camardese; Delfina Janiri; Lorenzo Moccia; Alessio Simonetti; Luigi Janiri; Gabriele Sani Journal: Int J Environ Res Public Health Date: 2022-06-16 Impact factor: 4.614
Authors: Alexandros N Vgontzas; Kristina Puzino; Julio Fernandez-Mendoza; Venkatesh Basappa Krishnamurthy; Maria Basta; Edward O Bixler Journal: J Clin Sleep Med Date: 2020-12-15 Impact factor: 4.062